Interestingly, in this review, we found that in 2 studies [35, 36], the combination of trastuzumab plus bevacizumab and chemotherapy produced very high pCR rates in HER2-positive IBC patients (57.0% and 63.5%, respectively), but these pCR rates were not higher than those in studies in which HER2-positive IBC patients were treated with single-agent trastuzumab and chemotherapy (66.7% and 54.0%, respectively) [34, 37]. This evidence concerns the gene ERBB2 and inflammatory breast carcinoma.